9-ING-41 is a GSK-3β inhibitor being tested in a Phase 1/2 clinical trial as a single agent and combined with chemotherapy in patients with refractory hematologic malignancies or solid tumors, including liver cancer. This evidence concerns the gene GSK3B and liver cancer.